Arrowhead Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Arrowhead Pharmaceuticals's earnings have been declining at an average annual rate of -53.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 6% per year.
Key information
-53.8%
Earnings growth rate
-52.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 6.0% |
Return on equity | -161.5% |
Net Margin | -2,741.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Revenue & Expenses Breakdown
How Arrowhead Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 20 | -539 | 121 | 446 |
31 Mar 24 | 35 | -471 | 119 | 390 |
31 Dec 23 | 182 | -297 | 113 | 368 |
30 Sep 23 | 241 | -205 | 109 | 337 |
30 Jun 23 | 256 | -181 | 117 | 320 |
31 Mar 23 | 273 | -150 | 125 | 298 |
31 Dec 22 | 278 | -155 | 135 | 301 |
30 Sep 22 | 243 | -176 | 137 | 284 |
30 Jun 22 | 250 | -154 | 141 | 269 |
31 Mar 22 | 263 | -112 | 123 | 258 |
31 Dec 21 | 144 | -183 | 104 | 228 |
30 Sep 21 | 138 | -141 | 85 | 202 |
30 Jun 21 | 108 | -126 | 64 | 178 |
31 Mar 21 | 89 | -110 | 56 | 151 |
31 Dec 20 | 80 | -103 | 55 | 137 |
30 Sep 20 | 88 | -85 | 54 | 127 |
30 Jun 20 | 124 | -24 | 52 | 105 |
31 Mar 20 | 139 | 10 | 46 | 91 |
31 Dec 19 | 164 | 53 | 35 | 84 |
30 Sep 19 | 169 | 68 | 27 | 81 |
30 Jun 19 | 137 | 46 | 25 | 72 |
31 Mar 19 | 95 | 10 | 23 | 66 |
31 Dec 18 | 47 | -29 | 20 | 58 |
30 Sep 18 | 16 | -54 | 19 | 53 |
30 Jun 18 | 14 | -54 | 18 | 51 |
31 Mar 18 | 22 | -44 | 16 | 51 |
31 Dec 17 | 31 | -35 | 13 | 54 |
30 Sep 17 | 31 | -34 | 20 | 49 |
30 Jun 17 | 23 | -46 | 25 | 49 |
31 Mar 17 | 13 | -60 | 32 | 46 |
31 Dec 16 | 4 | -75 | 42 | 40 |
30 Sep 16 | 0 | -82 | 25 | 61 |
30 Jun 16 | 0 | -84 | 41 | 39 |
31 Mar 16 | 0 | -81 | 40 | 37 |
31 Dec 15 | 0 | -89 | 36 | 39 |
30 Sep 15 | 0 | -92 | 35 | 47 |
30 Jun 15 | 0 | -90 | 32 | 45 |
31 Mar 15 | 0 | -85 | 30 | 44 |
31 Dec 14 | 0 | -71 | 28 | 37 |
30 Sep 14 | 0 | -59 | 25 | 23 |
30 Jun 14 | 0 | -50 | 19 | 17 |
31 Mar 14 | 0 | -44 | 16 | 13 |
31 Dec 13 | 0 | -37 | 13 | 10 |
Quality Earnings: ARWR is currently unprofitable.
Growing Profit Margin: ARWR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARWR is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.
Accelerating Growth: Unable to compare ARWR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARWR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ARWR has a negative Return on Equity (-161.48%), as it is currently unprofitable.